^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

COMPANY:
Delfi Diagnostics

i
Other names: Delfi Diagnostics
Related tests:
Evidence

News

19d
DELFI Diagnostics Selects Lahey Hospital & Medical Center to Administer New Lung Cancer Screening Test (PRNewswire)
"DELFI Diagnostics, Inc...has selected Lahey Hospital & Medical Center (LHMC), part of Massachusetts-based Beth Israel Lahey Health (BILH), to utilize its FirstLook Lung cancer screening test to help improve screening rates in the greater Boston area...Lahey will incorporate DELFI's blood-based lung cancer screening test in the primary care setting on patients eligible for lung cancer screening....In an independent validation, FirstLook Lung was shown to have very high sensitivity in a screening population, including detecting the earliest stages of the disease."
Commercial
|
FirstLook Lung
2ms
Florida Lung Health Coalition, with support from DELFI Diagnostics, RadNet, Inc., and The American Lung Association, to launch a revolutionary lung cancer screening program focused on early detection (PRNewswire)
"PALO ALTO, Calif…announced today, the Florida Lung Health Coalition and DELFI Diagnostics, supported by RadNet, Inc..and the American Lung Association, are collaborating to launch a pioneering initiative to transform lung cancer screening and detection in Florida…This new program, announced ahead of Lung Cancer Awareness Month in November, aims to significantly boost early detection rates in Florida where lung cancer screening rates are at only 15.8%, according to the Centers for Disease Control and Prevention Behavioral Risk Factor Surveillance System. The initiative will be funded through grants and corporate sponsorships by the partners, and it brings together leading healthcare organizations to address the critical need for accessible and efficient lung cancer screening."
Licensing / partnership
|
FirstLook Lung
2ms
DELFI Diagnostics Study on Cancer Treatment Monitoring Using Fragmentomes Featured in Nature Communications (PRNewswire)
P3 | N=564 | CAIRO5 (NCT02162563) | "DELFI Diagnostics...is announcing the publication...in Nature Communications that demonstrates the effectiveness of cell-free DNA (cfDNA) fragmentomes as a means of assessing tumor burden for treatment response, monitoring, and clinical outcome prediction. cfDNA fragmentomes are tumor and mutation-independent, and the approach described in the paper (called DELFI-Tumor Fraction or 'DELFI-TF') requires only 800ul of plasma....The new paper further demonstrates the characteristics of DELFI-TF in two independent validation cohorts. 'DELFI-TF is a locked machine learning classifier validated in two independent cohorts of colorectal and lung cancer patients and can detect clinical outcomes earlier than imaging. This work demonstrates the potential of DELFI-TF to estimate tumor burden for accurate treatment-response monitoring and clinical outcome prediction.'"
P3 data
2ms
Allegheny Health Network explores use of promising new blood-based test to enhance lung cancer detection (PRWeb)
"Allegheny Health Network (AHN) and DELFI Diagnostics, Inc...announced a collaboration to evaluate the effectiveness of DELFI Diagnostics' 'FirstLook' blood test to enhance lung cancer screening among western Pennsylvanians who are at risk for developing lung cancer – the leading cause of cancer-related deaths worldwide."
Licensing / partnership
|
FirstLook Lung
6ms
Indigenous Pact and DELFI Diagnostics Join Forces to Enhance Lung Cancer Screening in Tribal Communities (PRNewswire)
"Indigenous Pact..and DELFI Diagnostics...announced a partnership to utilize DELFI's FirstLook Lung to increase lung cancer screening and early detection in Tribal communities throughout the State of Washington...The collaboration to offer lung cancer screening with FirstLook's blood-based test will initiate in Washington and expand across Tribal Nations....On June 12-14, in San Diego, Indigenous Pact will host its inaugural Regional Tribal Summit. This summit will bring together Tribal leaders to discuss their communities' needs and how best to harness opportunities and address challenges. DELFI will participate in the event to further its understanding of how new technologies like the FirstLook Lung test can aid leaders in their goals to improve healthcare delivery across Indian Country."
Licensing / partnership
|
FirstLook Lung
6ms
Landmark blood-based AI lung cancer screening test study results published in Cancer Discovery (PRNewswire)
"DELFI Diagnostics, Inc...announces the publication of groundbreaking data in the prestigious journal Cancer Discovery from the company's L101 study, 'Clinical validation of a cell-free DNA fragmentome assay for augmentation of lung cancer early detection'. The report details the performance and potential of DELFI's FirstLook Lung test. This milestone study, led by top researchers in the field, marks a significant advancement in aiding blood-based cancer detection."
Clinical data
|
FirstLook Lung
6ms
DELFI Diagnostics Announces Equity Investment from the Merck Global Health Innovation Fund to Accelerate DELFI's Cancer Screening AI Fragmentomics Platform (PRNewswire)
"DELFI Diagnostics...announced an equity investment by the Merck Global Health Innovation Fund (GHIF), the corporate venture capital arm of Merck & Co., Inc, known as MSD outside the United States and Canada. The capital will accelerate and expand DELFI's development and commercialization of its cancer detection solutions. DELFI's fragmentomics technology applies artificial intelligence (AI) to whole-genome sequencing data to compare an individual's cell-free DNA (cfDNA) patterns and characteristics against populations with and without cancer."
Financing
7ms
OSF HealthCare and DELFI Diagnostics Announce Collaboration to Improve Lung Cancer Screening Rates (PRNewswire)
"OSF HealthCare...and DELFI Diagnostics, Inc...today announced a collaboration to utilize DELFI's FirstLook Lung blood-based cancer screening test to help improve screening rates. DELFI's collaboration with OSF was recently highlighted by the Biden Cancer Moonshot to expand accessibility to lung cancer screening...The goal is to further increase screening among eligible OSF patients by incorporating the FirstLook Lung liquid biopsy test into the primary care setting. The test will be offered at 18 locations initially, with plans to make it OSF Ministry-wide within a year....The test works by evaluating patterns of DNA fragments in the blood that reveal the presence of lung cancer."
Licensing / partnership
|
FirstLook Lung
8ms
City of Hope and DELFI Diagnostics announce collaboration to improve lung cancer screening rates in underserved areas of Los Angeles (PRNewswire)
"City of Hope...and DELFI Diagnostics...today announced a collaboration to utilize DELFI's FirstLook Lung, a blood-based lung cancer screening test, in a City of Hope clinical study to help improve screening rates in underserved communities in Los Angeles County. The test will be offered free of charge to eligible trial participants...Funded by a Discovery Boost grant from the American Cancer Society, awarded to Dan Raz...and the trial's principal investigator, the study that will evaluate use of the FirstLook Lung test to improve lung cancer screening rates in disadvantaged communities in the Los Angeles area. DELFI will make its liquid biopsy screening test, which will be submitted to the Food and Drug Administration for approval, available at various study locations, including City of Hope Antelope Valley...and ParkTree Community Health Center..."
Licensing / partnership
|
FirstLook Lung
8ms
DELFI Diagnostics to Present at American Association for Cancer Research Annual Meeting (PRNewswire)
"DELFI Diagnostics, Inc...today announced multiple upcoming poster and oral presentations at the American Association for Cancer Research (AACR) Annual Meeting, taking place in San Diego, California, from April 5-10, 2024. DELFI and independent researchers will highlight the performance of the company's next-generation, fragmentomics-based liquid biopsy platform to help detect early cancer and monitor treatment response."
Clinical data
|
FirstLook Lung
10ms
DELFI Diagnostics announces availability of new fragmentome-based cancer treatment monitoring assay (Delfi Diagnostics Press Release)
"DELFI Diagnostics, Inc...announced availability of the company's fragmentome-based research use only (RUO) cancer monitoring assay. The DELFI-Tumor Fraction (DELFI-TF) assay is a highly sensitive, inexpensive means of noninvasive measurement of tumor burden and assessing treatment response and resistance in patients with advanced cancer."
Clinical
12ms
DELFI Diagnostics supports proposed legislation to allow CMS to review new blood-based screening tests for lung cancer (PRNewswire)
"DELFI Diagnostics, Inc...announced support for the recently introduced Lung Cancer Screening and Prevention Act (H.R. 6693)...The proposed legislation would grant the Centers for Medicare & Medicaid Services (CMS) the authority to review U.S. Food and Drug Administration (FDA) approved or cleared new lung cancer screening tests as preventive services under the Agency's existing standards for coverage."
Medicare • Reimbursement
|
FirstLook Lung
1year
DELFI Diagnostics launches FirstLook Lung, an accessible, accurate new way to enhance lung cancer screening through a routine blood test (PRNewswire)
"DELFI Diagnostics, Inc...announced...the initial commercial introduction of FirstLook Lung. FirstLook is a blood test that offers a convenient, accurate and personalized result by determining the likelihood of detecting lung cancer through low-dose CT (LDCT), with a negative predictive value (NPV) of 99.7 percent."
Launch
|
FirstLook Lung
1year
DELFI Diagnostics to highlight breakthrough technology and completed clinical study in lung cancer detection (PRNewswire)
"DELFI Diagnostics, Inc...announced...that the company will participate in multiple sessions at the HLTH 2023 conference in Las Vegas, Nevada, and the CHEST 2023 Annual Meeting in Honolulu, Hawai'i, both taking place October 8-11, 2023...An oral presentation at CHEST will highlight new data from the DELFI-L101 Study, 'DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study,' a prospective, multicenter, case-control study among individuals eligible for lung cancer screening to train and independently validate the blood-based test for early cancer detection."
Clinical data
over1year
DELFI Diagnostics Licenses GEMINI Technology from Johns Hopkins University: Study Demonstrates High Performance for Early Stage Lung Cancer Detection When Integrated with DELFI Diagnostics’s Platform (PRNewswire)
"DELFI Diagnostics...has exclusively licensed a new, highly accurate method for identifying somatic genomic alterations in cell-free DNA (cfDNA) known as GEMINI, or GEnome-wide Mutational Incidence for Non Invasive detection of cancer....In a study published today in Nature Genetics, researchers showed that GEMINI, combined with the approach used by DELFI Diagnostics, could successfully identify early stage lung cancers – those cancers that are most critical to detect to change patient outcome."
Licensing / partnership
over1year
DELFI Diagnostics presents additional promising proof-of-concept data on its monitoring program at AACR 2023 (PRNewswire)
"DELFI Diagnostics, Inc...presented proof-of-concept data demonstrating how DELFI's platform can be used for monitoring the treatment of patients with advanced cancer without requiring any prior genomic information about the patient's tumor. The data were presented at the American Association for Cancer Research (AACR) 2023 Annual Meeting and builds on earlier studies showing the potential of using DELFI's technology for treatment monitoring."
Clinical data
over1year
Delfi Diagnostics to showcase breadth of its next-generation liquid biopsy platform at the American Association for Cancer Research Annual Meeting (PRNewswire)
"Delfi Diagnostics, Inc...will present multiple oral and poster presentations showcasing the performance of its next-generation liquid biopsy platform at the American Association for Cancer Research's 2023 annual meeting next month...The presentations from Delfi and other independent researchers using the DELFI platform will provide updates on Delfi's lung cancer screening clinical trials, describe the DELFI platform's ability to detect early stage ovarian cancer, and detail how it performs in monitoring the progress of metastatic colorectal cancer patients on chemotherapy."
Clinical data
2years
Positive liver cancer detection data published in Cancer Discovery shows further promise of Delfi's AI liquid biopsy platform (PRNewswire)
"Positive liver cancer detection data published in Cancer Discovery demonstrates the promise of Delfi Diagnostics' high-performance, accessible liquid biopsy platform in a new tumor type. Delfi had previously announced that it is developing a low-cost, highly sensitive blood test for lung cancer screening. The new findings, which will also be presented in Austin, Texas at AACR's Special Conference on Precision Prevention, Early Detection and Interception of Cancer, show how Delfi's platform could be applied in a second clinical context."
Clinical data
2years
Researchers to present proof-of-concept liver cancer detection data using the DELFI platform at AASLD The Liver Meeting® 2022 (PRNewswire)
"Researchers using the DELFI platform, a technology for a new class of high performance, accessible liquid biopsy tests being commercialized by Delfi Diagnostics, Inc., will present new data demonstrating its ability to accurately detect liver cancer in high risk and average risk individuals at The Liver Meeting 2022, the annual meeting of the American Association for the Study of Liver Disease."
Clinical data
2years
Delfi Diagnostics selected as the liquid biopsy partner for 4-IN-THE-LUNG-RUN: A large-scale European lung cancer screening study (PRNewswire)
"Delfi Diagnostics...has been selected as the liquid lung cancer biopsy partner in Europe's multi-national, randomized, prospective lung cancer screening trial known as 4-IN-THE-LUNG-RUN, or 4ITLR...Through 4ITLR, European investigators are studying how often – every year, or every other year – individuals should get screened if their initial CT scan is negative. Delfi's technology is paired to the study objectives by measuring whether Delfi can identify individuals in Europe's screen-eligible population who are most likely to benefit from a CT scan."
Clinical
over2years
Delfi Diagnostics announces $225 million Series B financing to develop globally accessible portfolio of liquid biopsy tests (PRNewswire)
"Delfi Diagnostics, Inc...announced a Series B funding of $225 million...This funding will support the continued development and commercialization of high-quality and accessible blood tests for single cancer early detection, multi-cancer early detection, and treatment monitoring."
Financing
over2years
Delfi Diagnostics to present at 2022 ASCO annual meeting on multiple applications for its next-generation liquid biopsy platform (PRNewswire)
"Delfi Diagnostics...will present updates at the 2022 annual meeting of the American Society for Clinical Oncology (ASCO) in Chicago June 3-7 describing multiple applications for its next-generation liquid biopsy platform...Delfi will present a trial-in-progress update on DELFI-L101, a prospective, case-control study to train and test classifiers for lung cancer detection."
Clinical data
over2years
Delfi Diagnostics enters into broad research agreement with top U.S. cancer center (PRNewswire)
"Delfi Diagnostics...has entered into a broad research agreement with Memorial Sloan Kettering Cancer Center's Biomarker Development Program...The agreement creates a framework for Delfi and MSK researchers to work together on a range of projects studying Delfi's liquid biopsy platform, advancing their shared mission of developing high performing cancer testing."
Licensing / partnership
over2years
Delfi Diagnostics Initiates 15,000-Patient Prospective Lung Cancer Screening Trial (PRNewswire)
"Delfi Diagnostics...has enrolled the first participants in the CASCADE-LUNG study. CASCADE-LUNG is a prospective, multi-center trial that will enroll up to 15,000 participants at the time of their low dose CT (LDCT) lung cancer screening and will add to the clinical validation of Delfi's liquid biopsy test for lung cancer detection."
Enrollment open
over2years
Delfi Researchers and Founders to Present at American Association for Cancer Research (AACR) 2022 Annual Meeting (PRNewswire)
"Delfi Diagnostics...will present new findings from its fragmentomics-based platform at the American Association for Cancer Research (AACR) 2022 Annual Meeting....Delfi Founder and CEO Victor Velculescu was recognized by AACR for his stellar contributions involving the discovery of genomic alterations in cancer cells and for developing non-invasive cancer detection technologies."
Clinical data